Aspekte der kombinierten Strahlen- und Chemotherapie bei gastrointestinalen Tumoren

  • W. Rhomberg
Conference paper

Zusammenfassung

Die Anwendung einer sequentiellen oder gleichzeitigen Radio-Chemotherapie hat in den letzten Jahren breites Interesse gefunden. Dieser Trend wurde unter anderem von der Einsicht in die beschränkten Therapiemöglichkeiten und der Hoffnung auf die Überwindung des Resistenzproblems genährt. Erwünscht sind überadditive lokale Effekte oder komplexe Wirkungen auf das Gesamtgeschehen einer Krebserkrankung.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Byfield JE, Calabro-Jones P, Klisak I et al. (1982) Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5 fluorouracil or ftorafur and X rays. Int J Radiat Oncol Biol Phys 8: 1923–1933PubMedCrossRefGoogle Scholar
  2. 2.
    Cassady JR, Richter MP, Piro AJ, Jaffe N (1975) Radiation-Adriamycin interactions: preliminary clinical observations. Cancer 36: 946–949PubMedCrossRefGoogle Scholar
  3. 3.
    Clagett-Carr K, Sarosy G, Plowman J et al. (1988) N-Methylformamide: Cytotoxic, Radiosensitizer, or Chemosensitizer (review article). J Clin Oncol 6: 906–918PubMedGoogle Scholar
  4. 4.
    Danjoux CE, Gelber RD, Cotton GE, Klaassen DJ (1985) Combination chemoradiotherapy for residual, recurrent or inoperable carcinoma of the rectum: ECOG Study (EST 3276). Int J Radiat Oncol Biol Phys 11: 765–771PubMedCrossRefGoogle Scholar
  5. 5.
    Dewit L, Oussoren Y, Bartelink H, Thomas HD (1989) The effect of cisdiaminedichloroplatinum (II) on radiation damage in mouse rectum after fractionated irradiation. Radiother Oncol 16: 121–128PubMedCrossRefGoogle Scholar
  6. 6.
    Double EB (1985) The use of platinum chemotherapy to potentiate radiotherapy. Platinum Metals Rev 29: 118–125Google Scholar
  7. 7.
    Gastrointestinal Tumor Study Group (1985) Prolongation of the disease free interval in surgically treated rectal carcinoma. N Engl J Med 312: 1465–1472CrossRefGoogle Scholar
  8. 8.
    Gilbert JM, Hellmann K, Evans M et al. (1982) Adjuvant oral Razoxane (ICRF 159) in resectable colorectal cancer. Cancer Chemother Pharmacol 8: 293–299PubMedCrossRefGoogle Scholar
  9. 9.
    Glover D, Glick JH, Weiler C et al. (1986) WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 4: 548–588Google Scholar
  10. 10.
    Hellmann K, Burrage K (1969) Control of malignant metastases by ICRF 159. Nature 224: 273–275PubMedCrossRefGoogle Scholar
  11. 11.
    Hellmann K, Murkin CE (1974) Synergism of ICRF 159 and radiotherapy in experimental tumors. Cancer 34: 1033–1039PubMedCrossRefGoogle Scholar
  12. 12.
    Hellmann K, Gilbert J, Evans M et al. (1986) Randomized trial of oral razoxane in resectable colorectal cancer: five-year follow up. Clin Expl Metastasis 4: 326Google Scholar
  13. 13.
    Hellmann K, Gilbert J, Evans M et al. (1987) Effect of razoxane on metastases from colorectal cancer. Clin Expl Metastasis 5: 3–8CrossRefGoogle Scholar
  14. 14.
    Holsti LR, Mattson K, Niiranen A et al. (1987) Enhancement of radiation effects by alpha interferon in the treatment of small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 13: 1161–1166PubMedCrossRefGoogle Scholar
  15. 15.
    Horwich A, Lokich JJ, Bloomer WD (1975) Doxorubicin, radiotherapy and esophageal stricture. Lancet 2: 561–562PubMedCrossRefGoogle Scholar
  16. 16.
    Ito H, Melstrich ML, Barkley Th et al. (1986) Protection of acute and late radiation damage of the gastrointestinal tract by WR-2721. Int J Radiat Oncol Biol Phys 12: 211–219PubMedCrossRefGoogle Scholar
  17. 17.
    Kanclerz A, Chapman JD (1988) Influence of Misonidazole, SR 2508, RSU 1069 and WR-2721 on spontaneous metastases in C57BL mice. Int J Radiat Oncol Biol Phys 14: 309–316PubMedCrossRefGoogle Scholar
  18. 18.
    Kligerman MM, Shapiro DM (1957) Augmentation of radiotherapeutic effect of cancer chemotherapy. Radiology 69: 194–200PubMedGoogle Scholar
  19. 19.
    Le Serve AW, Hellmann K (1972) Metastases and the normalization of tumor blood vessels by ICRF 159: a new type of drug action. Br Med J 1: 597–601PubMedCrossRefGoogle Scholar
  20. 20.
    Looney WB, Hopkins HA, Mac Leod MS et al. (1979) Solid tumor models for the assessment of different treatment modalities: XII. Combined chemo-radiotherapy: variation of time intervall between administration of 5 fluorouracil and radiation and its effect on the control of tumor growth. Cancer 44: 437–447PubMedCrossRefGoogle Scholar
  21. 21.
    Looney WB (1988) Alternating chemotherapy and radiotherapy. NCI Monogr 6: 85–94PubMedGoogle Scholar
  22. 22.
    Milas L, Hunter N, Ito H, Peters U (1984) Effect of tumor type, size, and endpoint on tumor radioprotection by WR-2721. Int J Radiat Oncol Biol Phys 10: 41–48PubMedCrossRefGoogle Scholar
  23. 23.
    Nigro ND, Vaitkevicius VK, Considine B (1974) Combined therapy for cancer of the anal canal. A preliminary report. Dis Colon Rectum 17: 354–356PubMedCrossRefGoogle Scholar
  24. 24.
    Osieka R (1988) Chemosensibilisierung. Tumor Diagn Ther 9/Sonderheft 1: 7–11Google Scholar
  25. 25.
    Phillips TL, Wharam MD, Margolis LW (1975) Modification of radiation injury to normal tissues by chemotherapeutic agents. Cancer 35: 1678PubMedCrossRefGoogle Scholar
  26. 26.
    Phillips TL, Fu KK (1976) Quantification of combined radiation therapy effects on critical normal tissues. Cancer 37: 1186–1200PubMedCrossRefGoogle Scholar
  27. 27.
    Queißer W, Heim ME (1989) Combined modality of radiation and chemotherapy for the treatment of gastric carcinoma. Onkologie 12: 156–160PubMedCrossRefGoogle Scholar
  28. 28.
    Rhomberg W, Eiter H (1989) Studien zur Strahlensensibilität inoperabler u. rezidivierter Rektumkarzinome. Strahlenther Onkol 165: 28–33PubMedGoogle Scholar
  29. 29.
    Rominger CJ, Gunderson LL, Gelber RD et al. (1985) Radiation therapy alone or in combination with chemotherapy in the treatment of residual or inoperable carcinoma of the rectum or rectosigmoid or pelvic recurrence following surgery. RTOG. Amer J Clin Oncol 8: 118–127CrossRefGoogle Scholar
  30. 30.
    Rubin Ph, Constine LS, Van Ess JD (1988) Scoring of late toxic effects–interaction of two modalities. NCI Monogr 6: 9–18PubMedGoogle Scholar
  31. 31.
    Schenken LL, Burholt DR, Ronald F et al. (1976) The modification of gastrointestinal tolerance and responses to abdominal irradiation by chemotherapeutic agents. Radiology 120: 417–420PubMedGoogle Scholar
  32. 32.
    Siemann DW (1982) Potentiation of chemotherapy by hypoxic cell radiation sensitizers–a review. Int J Radiat Oncol Biol 8: 1029–1034CrossRefGoogle Scholar
  33. 33.
    Spanos WJ Jr, Wassermann T, Meoz R et al. (1987) Palliation of advanced pelvic malignant disease with large fraction pelvic radiation and misonidazole: final report of RTOG phase I/II study. Int J Radiat Oncol Biol Phys 13: 1479–1482PubMedCrossRefGoogle Scholar
  34. 34.
    Streffer Ch (1988) Experimentelle Grundlagen der Kombination ionisierender Strahlen mit zytostatischen Substanzen. Tumor Diagn Ther 9/Sonderheft 1: 2–6Google Scholar
  35. 35.
    Tannock JF (1989) Combined modality treatment with radiotherapy and chemotherapy (review article). Radiother Oncol 16: 83–101PubMedCrossRefGoogle Scholar
  36. 36.
    Takahashi I, Nagai T, Miyaishi K et al. (1986) Clinical study of the radioprotective effects of Amifostine (YM-08310, WR-2721) on chronic radiation injury. Int J Radiat Oncol Biol Phys 12: 935–938PubMedCrossRefGoogle Scholar
  37. 37.
    Vongtama V, Douglass HO, Moore RH et al. (1975) Endresults of radiation therapy, alone and combination with 5-fluorouracil in colorectal cancers. Cancer 36: 2020–2025PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • W. Rhomberg

There are no affiliations available

Personalised recommendations